At 11.7% CAGR, Middle East & Africa Human Vaccine Adjuvants Market is Projected to be Worth US$ 119.37 Million by 2030, says Business Market Insights

According to Business Market Insights' research, the Middle East & Africa human vaccine adjuvants market was valued at US$ 49.18 million in 2022 and is expected to reach US$ 119.37 million by 2030, registering a CAGR of 11.7% from 2022 to 2030. Rising trend of personalized vaccines and rising prevalence of chronic diseases are among the critical factors attributed to drive the Middle East & Africa human vaccine adjuvants market growth.

Precision or personalized vaccines are a growing trend in the Middle East & Africa human vaccine adjuvants market. These vaccines target specific genetic or molecular characteristics of a patient's disease, assisting the production of vaccines tailored to each patient's unique immune response. The technique can potentially improve vaccination efficacy and safety, leading to increased interest in personalized vaccines for treating diseases such as cancer, infectious diseases, and autoimmune disorders.

Adjuvants that can boost the immune response to these tailored vaccines are required to produce personalized vaccines. Adjuvants are essential in stimulating the immune system to develop a targeted and powerful response to the vaccine's specific antigens. As a result, there is an increasing demand for adjuvants that can effectively boost immune responses to personalized vaccines. In recent years, there has been a strong emphasis on R&D efforts to identify and create adjuvants that can effectively increase the immune response to personalized vaccines. For instance, in December 2022, Moderna and Merck announced mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA(R) (pembrolizumab). Adjuvant treatment with mRNA-4157/V940 in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared with KEYTRUDA alone. Regulatory bodies and healthcare organizations recognize personalized vaccines' potential for enhancing public health outcomes. Thus, adjuvants that effectively improve the immune response to personalized vaccinations are increasingly being developed, enhancing vaccine efficacy and safety. This trend drives substantial innovation and investment in the Middle East & Africa human vaccine adjuvants market.

On the contrary, manufacturing complexities and regulatory challenges hampers the growth of Middle East & Africa human vaccine adjuvants market.

Based on type, the Middle East & Africa human vaccine adjuvants market is segmented particulate adjuvant, emulsion adjuvant, combination adjuvant, and others. The particulate adjuvant segment held 39.2% market share in 2022, amassing US$ 19.26 million. It is projected to garner US$ 46.11 million by 2030 to register 11.5% CAGR during 2022-2030.

In terms of application, the Middle East & Africa human vaccine adjuvants market is categorized into influenza, hepatitis, human papilloma virus (HPV), and others. The influenza segment held 37.7% share of Middle East & Africa human vaccine adjuvants market in 2022, amassing US$ 18.55 million. It is anticipated to garner US$ 46.60 million by 2030 to expand at 12.2% CAGR during 2022-2030.

By end user, the Middle East & Africa human vaccine adjuvants market is segmented into pharmaceutical and biotechnology companies, CMOs and CROs, and others. The pharmaceutical and biotechnology companies segment held 48.9% share of Middle East & Africa human vaccine adjuvants market in 2022, amassing US$ 24.06 million. It is projected to garner US$ 60.44 million by 2030 to expand at 12.2% CAGR from 2022 to 2030.

By country, the Middle East & Africa human vaccine adjuvants market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Our regional analysis states that Saudi Arabia captured 29.4% share of Middle East & Africa human vaccine adjuvants market in 2022. It was assessed at US$ 15.15 million in 2022 and is likely to hit US$ 38.96 million by 2030, registering a CAGR of 12.5% during 2022-2030.

Key players operating in the Middle East & Africa human vaccine adjuvants market are Novartis AG, CSL Ltd, Seppic SA, Croda International Plc, Novavax Inc, and Phibro Animal Health Corp, among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com